Literature DB >> 11451043

Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling.

R Gomeni1, V Teneggi, L Iavarone, L Squassante, A Bye.   

Abstract

PURPOSE: A population pharmacokinetic-pharmacodynamic model accounting for placebo effect was used to relate nicotine concentration and enforced smoking cessation craving score measured by the Tiffany rating scale short form.
METHODS: Twenty-four smokers were enrolled in a placebo-controlled, randomized, double-blind, three periods, crossover trial. The study objective was to describe the nicotine-induced changes on craving scores. Two modeling strategies based on a mechanistic (indirect response models with drug-related inhibition on the k(in) synthesis rate and with a drug-related stimulation of the k(out) removal rate were evaluated) and a probabilistic (logistic regression) approach were used.
RESULTS: Placebo response model properly fitted the circadian changes on craving scores. The analysis revealed that the indirect response model with inhibition on k(in) was the preferred model for the smoking data whereas the preferred model for the Nicotine Replacement Therapy data was the one with stimulation on k(out). The logistic analysis showed that the nicotine concentration was a significant predictor of reduction in craving during the free-smoking period.
CONCLUSIONS: Nicotine dosage regimen can influence the nicotine mechanism of action: an instantaneous delivery at an individually selected time seems to inhibit the onset of craving while constant delivery at a pre-defined time seems to attenuate the craving.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451043     DOI: 10.1023/a:1011070814530

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Role of dosage regimen in controlling indirect pharmacodynamic responses.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

2.  The development and initial validation of a questionnaire on smoking urges.

Authors:  S T Tiffany; D J Drobes
Journal:  Br J Addict       Date:  1991-11

3.  Chronopharmacokinetics of nicotine.

Authors:  J M Gries; N Benowitz; D Verotta
Journal:  Clin Pharmacol Ther       Date:  1996-10       Impact factor: 6.875

4.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

5.  Cigarette smoking among adults--United States, 1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1994-12-23       Impact factor: 17.586

6.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment.

Authors:  K O Fagerström
Journal:  Addict Behav       Date:  1978       Impact factor: 3.913

7.  Nicotine blood levels and subjective craving for cigarettes.

Authors:  M E Jarvik; D C Madsen; R E Olmstead; P N Iwamoto-Schaap; J L Elins; N L Benowitz
Journal:  Pharmacol Biochem Behav       Date:  2000-07       Impact factor: 3.533

8.  The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.

Authors:  M C Fiore; S S Smith; D E Jorenby; T B Baker
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

9.  How effective is nicotine replacement therapy in helping people to stop smoking?

Authors:  J L Tang; M Law; N Wald
Journal:  BMJ       Date:  1994-01-01

10.  Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation.

Authors:  N G Schneider; M E Jarvik; A B Forsythe
Journal:  Addict Behav       Date:  1984       Impact factor: 3.913

View more
  9 in total

1.  In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation.

Authors:  Roberto Gomeni; Carla Dangeli; Alan Bye
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

2.  Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving.

Authors:  Vincenzo Teneggi; Lisa Squassante; Laura Iavarone; Stefano Milleri; Alan Bye; Roberto Gomeni
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

3.  Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Authors:  Ulrika Wählby; Katalin Matolcsi; Mats O Karlsson; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

4.  Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients.

Authors:  Mayumi Hasegawa; Yasuhiko Imai; Masaki Hiraoka; Kiyomi Ito; Amit Roy
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-15       Impact factor: 2.745

5.  Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

Authors:  Maria C Kjellsson; Per-Henrik Zingmark; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-23       Impact factor: 2.745

6.  Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Hélène M Faessel; Theodore C Lee; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2014-08-21       Impact factor: 4.244

7.  Examining temptation to drink from an existential perspective: Associations among temptation, purpose in life, and drinking outcomes.

Authors:  Corey R Roos; Megan Kirouac; Matthew R Pearson; Brandi C Fink; Katie Witkiewitz
Journal:  Psychol Addict Behav       Date:  2015-03-02

8.  Sweet/Fat Preference Taste in Subjects Who are Lean, Obese and Very Obese.

Authors:  Jennifer Leohr; Maria C Kjellsson
Journal:  Pharm Res       Date:  2020-11-19       Impact factor: 4.200

9.  Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling.

Authors:  Jennifer Leohr; Maria C Kjellsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-07-01       Impact factor: 2.745

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.